Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication
Autore:
Lee, TM; Su, SF; Tsai, CH; Lee, YT; Wang, SS;
Indirizzi:
Natl Taiwan Univ Hosp, Coll Med, Cardiol Sect, Dept Internal Med, New York, NY 10002 USA Natl Taiwan Univ Hosp New York NY USA 10002 l Med, New York, NY 10002 USA Natl Cheng Kung Univ, Coll Med, Dept Clin Pharm, Tainan 70101, Taiwan NatlCheng Kung Univ Tainan Taiwan 70101 lin Pharm, Tainan 70101, Taiwan Natl Taiwan Univ Hosp, Coll Med, Dept Surg, Cardiol Sect, New York, NY 10002 USA Natl Taiwan Univ Hosp New York NY USA 10002 Sect, New York, NY 10002 USA
Titolo Testata:
CLINICAL SCIENCE
fascicolo: 3, volume: 101, anno: 2001,
pagine: 305 - 311
SICI:
0143-5221(200109)101:3<305:DEOCAP>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
PERIPHERAL ARTERIAL-DISEASE; INTRAMUSCULAR GENE-TRANSFER; SMOOTH-MUSCLE CELLS; DOUBLE-BLIND TRIAL; TISSUE PERFUSION; SKELETAL-MUSCLE; LIMB ISCHEMIA; RABBIT MODEL; ANGIOGENESIS; THERAPY;
Keywords:
cilostazol; intermittent claudication; pentoxifylline; peripheral vascular disease; phosphodiesterase inhibitor; vascular endothelial growth factor;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Lee, TM Natl Taiwan Univ Hosp, Coll Med, Cardiol Sect, Dept Internal Med, New York, NY 10002 USA Natl Taiwan Univ Hosp New York NY USA 10002 ew York, NY 10002 USA
Citazione:
T.M. Lee et al., "Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication", CLIN SCI, 101(3), 2001, pp. 305-311

Abstract

Cilostazol is a new phosphodiesterase inhibitor with anti-platelet and vasodilatory properties. Cilostazol and pentoxifylline are the only two drugs that have been approved for the treatment of patients with intermittent claudication. However, the mechanisms by which exercise tolerance is improved remain unclear. Vascular endothelial growth factor (VEGF) is a potent endothelial mitogen that results in angiogenesis when overexpressed in human subjects. To assess the potential role of VEGF in the improvement in exercise tolerance, we investigated plasma levels of VEGF in 50 patients with intermittent claudication who were allocated randomly to groups receiving cilostazol (n = 17), pentoxifylline (n = 17) or placebo (n = 16). Patients given either cilostazol or pentoxifylline showed a significant improvements in maximal walking distance compared with the placebo group (34 m and 33 m respectively, compared with 5 m; both P < 0.05). Neither cilostazol nor pentoxifylline increased the ankle-brachial index after treatment. Circulating VEGF levels were increased (from 116 +/- 29 to 169 +/- 45 pg/ml; P = 0.002), andthe levels of VEGF were correlated significantly with exercise tolerance in a positive direction (r = 0.88, P = 0.004), in those patients treated with cilostazol that did not have diabetes mellitus. In contrast, VEGF levels remained stable after the administration of pentoxifylline. These findings suggest that VEGF may contribute to the cilostazol-related improvement in exercise tolerance in non-diabetic patients. However, pentoxifylline did notaffect VEGF levels, although a similar improvement in maximal walking distance was achieved. Thus the mechanisms involved in the pentoxifylline-treated group were different from those in the cilostazol-treated group, and require further study.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/11/20 alle ore 10:45:24